AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25281031 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper histidine treatment (early treatment prior to onset of symptoms)
Number of subjects: 60
Study 25281041 — intervention group
Group type: EXPERIMENTAL
Intervention: Old formulation of UFH
Number of subjects: 20
Study 25281041 — intervention group
Group type: COMPARATOR
Intervention: New formulation of UFH
Number of subjects: 20
Study 25281041 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of UFH
Number of subjects: 20
Study 25281177 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma ultrasound performed by HEMS providers
Number of subjects: 293
Study 25281400 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin dosed at 5 mg/kg three times a week
Number of subjects: 6
Study 25281436 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-detector computed tomography angiography (MDCTA)
Number of subjects: 371
Study 25282032 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urinary albumin-to-creatinine ratio (UACR)
Number of subjects: 144
Study 25282032 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher UACR
Number of subjects: 144
Study 25282032 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased UACR
Number of subjects: 144
Study 25283266 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib at a starting dose of 5 mg b.i.d.
Number of subjects: 64
Study 25283752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rett syndrome females
Number of subjects: 0
Study 25283752 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 0
Study 25283752 — intervention group
Group type: EXPERIMENTAL
Intervention: Milder mutations
Number of subjects: 0
Study 25283752 — intervention group
Group type: EXPERIMENTAL
Intervention: Milder clinical presentation
Number of subjects: 0
Study 25283752 — intervention group
Group type: EXPERIMENTAL
Intervention: Puberty synchrony
Number of subjects: 0
Study 25284275 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab retreatment (80 mg initial dose, followed by 40 mg every-other-week for 16 weeks)
Number of subjects: 133
Study 25284275 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab retreatment
Number of subjects: 133
Study 25284600 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended criteria lungs transplanted after prolonged ex vivo lung perfusion
Number of subjects: 0
Study 25284600 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable device for ex vivo lung perfusion
Number of subjects: 0
Study 25284629 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors used prophylactically for hostile proximal neck anatomy
Number of subjects: 319
Study 25284629 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors used for type Ia endoleak during initial endograft deployment
Number of subjects: 319
Study 25284629 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors used for endograft migration
Number of subjects: 319
Study 25284629 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoAnchors used in conjunction with extender cuffs after unsatisfactory endograft deployment
Number of subjects: 319
Study 25284629 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up imaging after EndoAnchor implantation
Number of subjects: 319
Study 25284629 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prophylactic patients
Number of subjects: 319
Study 25284629 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision patients treated for type Ia endoleak
Number of subjects: 319
Study 25284629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sac regression >5 mm in patients with 1-year imaging
Number of subjects: 319
Study 25285006 — intervention group
Group type: EXPERIMENTAL
Intervention: Kynurenine/tryptophan ratio
Number of subjects: 86
Study 25285006 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-1β concentrations
Number of subjects: 86
Study 25285006 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ratios of IL-18/IL-10
Number of subjects: 86
Study 25285006 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ratios of IFNγ/IL-10
Number of subjects: 86
Study 25285006 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ratios of IL-1β/IL-10
Number of subjects: 86
Study 25285006 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-1β
Number of subjects: 86
Study 25285126 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-D (two doses at 12 and 18 months)
Number of subjects: 123
Study 25285126 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal serogroup C conjugate vaccine (MCC, one dose at 12 months)
Number of subjects: 123
Study 25285126 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib (administered concomitantly with MenACYW-D)
Number of subjects: 123
Study 25285269 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial spirometry for COPD diagnosis
Number of subjects: 187
Study 25285269 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory spirometry after three months
Number of subjects: 187
Study 25285269 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with tiotropium for newly diagnosed COPD patients
Number of subjects: 187
Study 25285269 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial and confirmatory spirometry
Number of subjects: 187
Study 25285572 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PI)
Number of subjects: 33
Study 25285572 — intervention group
Group type: COMPARATOR
Intervention: No protease inhibitors (Control)
Number of subjects: 33
Study 25286053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin treatment before the first islet infusion; induction therapy with anti-thymocyte globulin (ATG); short-term treatment with steroids and interleukin-1Ra; maintenance therapy with rapamycin+mycophenolate mofetil
Number of subjects: 10
Study 25286053 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with anti-thymocyte globulin (ATG)
Number of subjects: 10
Study 25286053 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance immunosuppression
Number of subjects: 10
Study 25286173 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactam and macrolide combination treatment
Number of subjects: 580
Study 25286173 — intervention group
Group type: COMPARATOR
Intervention: β-lactam monotherapy
Number of subjects: 580
Study 25287104 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Fatigue Syndrome (CFS)
Number of subjects: 120
Study 25287104 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 120
Study 25287572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisomy X girls (35 subjects)
Number of subjects: 35
Study 25287572 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (70 subjects)
Number of subjects: 35
Study 25287822 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg per day plus capecitabine 1,500 mg/m2 per day
Number of subjects: 72
Study 25288018 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly rituximab consolidation (375 mg/m², four times infusion) after four cycles of R-CHOP21
Number of subjects: 51
Study 25288018 — intervention group
Group type: COMPARATOR
Intervention: Historical case-matched control group treated with six cycles of R-CHOP21
Number of subjects: 51
Study 25288099 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence Utility Index (IUI)
Number of subjects: 442
Study 25288099 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-attribute utility function (MAUF)
Number of subjects: 442
Study 25288198 — intervention group
Group type: EXPERIMENTAL
Intervention: CV9202 vaccination combined with local radiation (5 GY per day for four successive days)
Number of subjects: 0
Study 25288198 — intervention group
Group type: EXPERIMENTAL
Intervention: CV9202 vaccination
Number of subjects: 0
Study 25288198 — intervention group
Group type: EXPERIMENTAL
Intervention: Local radiation
Number of subjects: 0
Study 25288566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med-Diet) adherence
Number of subjects: 801
Study 25288566 — intervention group
Group type: EXPERIMENTAL
Intervention: History of stroke/TIA
Number of subjects: 801
Study 25288566 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil consumption
Number of subjects: 801
Study 25288566 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine consumption
Number of subjects: 801
Study 25288566 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 801
Study 25289522 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir, single 75 mg dose administered before APD treatment.
Number of subjects: 10
Study 25290090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg once daily plus capecitabine 1000 mg m(-2) twice daily
Number of subjects: 32
Study 25290090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib plus capecitabine
Number of subjects: 32
Study 25290534 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-apposing covered self-expanding metal stent (LACSEMS)
Number of subjects: 33
Study 25290534 — intervention group
Group type: COMPARATOR
Intervention: Double-pigtail stents (control)
Number of subjects: 33
Study 25292153 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25293603 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation as a management strategy
Number of subjects: 0
Study 25293603 — intervention group
Group type: COMPARATOR
Intervention: Hernia repair
Number of subjects: 0
Study 25293768 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (4 infusions of 375 mg/m²)
Number of subjects: 248
Study 25293768 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (2 fixed 1-g infusions 2 weeks apart)
Number of subjects: 248
Study 25293768 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 248
Study 25293773 — intervention group
Group type: EXPERIMENTAL
Intervention: Local radiotherapy to solitary lymphoma nodes and intranodal injections of low-dose rituximab (5 mg), immature autologous dendritic cells, and granulocyte-macrophage colony-stimulating factor, repeated 3 times targeting different lymphoma nodes
Number of subjects: 14
Study 25294897 — intervention group
Group type: EXPERIMENTAL
Intervention: Refametinib plus sorafenib (refametinib 50 mg twice daily, sorafenib 200 mg morning/400 mg evening, with possible escalation to 400 mg twice daily from cycle 2)
Number of subjects: 95
Study 25294897 — intervention group
Group type: EXPERIMENTAL
Intervention: Refametinib plus sorafenib
Number of subjects: 95
Study 25295410 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with a history of pneumothorax
Number of subjects: 9062
Study 25295410 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased percent CT emphysema
Number of subjects: 9062
Study 25295410 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased pleural-based emphysema
Number of subjects: 9062
Study 25295410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime smoking intensity
Number of subjects: 9062
Study 25295432 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-treated patients
Number of subjects: 50
Study 25295432 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 25295500 — intervention group
Group type: EXPERIMENTAL
Intervention: self-inactivating (SIN) γ-retrovirus vector containing deletions in viral enhancer sequences expressing γc (SIN-γc)
Number of subjects: 9
Study 25295646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) up to 70 mg/day for 5 weeks
Number of subjects: 24
Study 25295646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts-immediate release (MAS-IR) up to 45 mg/day for 5 weeks
Number of subjects: 24
Study 25295646 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) for 1 week
Number of subjects: 24
Study 25295646 — intervention group
Group type: COMPARATOR
Intervention: Placebo washout for 3 weeks
Number of subjects: 24
Study 25295805 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental atopy
Number of subjects: 501
Study 25295805 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher paternal education
Number of subjects: 501
Study 25295805 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent house cleaning
Number of subjects: 501
Study 25295805 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping a pet at home during pregnancy
Number of subjects: 501
Study 25295805 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer breast-feeding
Number of subjects: 501
Study 25295805 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exposure to increased concentrations of particulate matter 10
Number of subjects: 501
Study 25296268 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood-onset asthma
Number of subjects: 590
Study 25296268 — intervention group
Group type: COMPARATOR
Intervention: Subjects without childhood-onset asthma
Number of subjects: 590
Study 25296762 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-SFA reduction (3.68-13.67 g)
Number of subjects: 60
Study 25296762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SFA reduction (>13.67 g)
Number of subjects: 60
Study 25296762 — intervention group
Group type: COMPARATOR
Intervention: Low-SFA reduction (<3.68 g)
Number of subjects: 60
Study 25296772 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombophilia panel measured in previously treated patients with chronic immune thrombocytopenia enrolled in an eltrombopag trial.
Number of subjects: 167
Study 25296772 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of multiple baseline thrombophilia risk markers.
Number of subjects: 167
Study 25297720 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 0
Study 25297720 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 0
Study 25297720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 0
Study 25297720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir/lopinavir
Number of subjects: 0
Study 25297720 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 0
Study 25298356 — intervention group
Group type: EXPERIMENTAL
Intervention: AbsorbTM BVS 1.1 implantation
Number of subjects: 0
Study 25298411 — intervention group
Group type: EXPERIMENTAL
Intervention: Short eyes (axial length <22.5 mm)
Number of subjects: 8
Study 25298411 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium eyes (axial length 22.51-25.50 mm)
Number of subjects: 8
Study 25298411 — intervention group
Group type: EXPERIMENTAL
Intervention: Long eyes (axial length >25.52 mm)
Number of subjects: 8
Study 25299251 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical management practices of dengue by physicians
Number of subjects: 817
Study 25299251 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of early signs of shock and warning signs for severe dengue
Number of subjects: 817
Study 25299251 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of corticosteroids and prophylactic platelet transfusions
Number of subjects: 817
Study 25299251 — intervention group
Group type: EXPERIMENTAL
Intervention: Best treatment options for dengue patients with refractory shock
Number of subjects: 817
Study 25299391 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (MEB; 500 mg)
Number of subjects: 5830
Study 25299391 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (ALB; 400 mg)
Number of subjects: 5830
Study 25300734 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber diet intervention
Number of subjects: 204
Study 25300734 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association diet intervention
Number of subjects: 204
Study 25301151 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Pulse System
Number of subjects: 20
Study 25301172 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-mediated CD/5-FC prodrug activator gene therapy
Number of subjects: 0
Study 25301172 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FC
Number of subjects: 0
Study 25301367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (3 cigarettes in one hour)
Number of subjects: 0
Study 25301708 — intervention group
Group type: EXPERIMENTAL
Intervention: XmAb5574 (MOR00208)
Number of subjects: 27
Study 25301783 — intervention group
Group type: EXPERIMENTAL
Intervention: New risk score for one-year mortality developed from 12 independent predictors.
Number of subjects: 10568
Study 25301783 — intervention group
Group type: EXPERIMENTAL
Intervention: New risk score for one-year mortality with excellent discrimination (c-statistic=0.81).
Number of subjects: 10568
Study 25301783 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score stratification for one-year mortality.
Number of subjects: 10568
Study 25301783 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of high-risk patients using the risk score.
Number of subjects: 10568
Study 25302057 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drink
Number of subjects: 8
Study 25302057 — intervention group
Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 8
Study 25302057 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 8
Study 25303490 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (r-hCG) 25 μg iv administration
Number of subjects: 28
Study 25303490 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 28
Study 25304008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin 5700 IU subcutaneous (s.c.)
Number of subjects: 35
Study 25304008 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin 2850 IU subcutaneous (s.c.)
Number of subjects: 35
Study 25304129 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial PPI responders
Number of subjects: 783
Study 25304129 — intervention group
Group type: COMPARATOR
Intervention: Treatment-naïve patients
Number of subjects: 783
Study 25304129 — intervention group
Group type: COMPARATOR
Intervention: Treatment-naïve patients after PPI therapy
Number of subjects: 783
Study 25304161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-innervated dorsal digital flap
Number of subjects: 73
Study 25304161 — intervention group
Group type: COMPARATOR
Intervention: Single-innervated flap
Number of subjects: 73
Study 25304476 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain recorded at 24 hours, assessed at 8 weeks, 6 months, and 12 months using questionnaires of pain intensity and interference.
Number of subjects: 381
Study 25304612 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25304614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyskeratosis congenita
Number of subjects: 4
Study 25304614 — intervention group
Group type: COMPARATOR
Intervention: Fanconi anemia
Number of subjects: 4
Study 25304614 — intervention group
Group type: COMPARATOR
Intervention: Diamond-Blackfan anemia
Number of subjects: 4
Study 25304614 — intervention group
Group type: COMPARATOR
Intervention: Shwachman-Diamond syndrome
Number of subjects: 4
Study 25304641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg daily and ribavirin starting at 400 mg daily (adjusted according to creatinine clearance and hemoglobin values) for 24 weeks
Number of subjects: 40
Study 25304641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin combination therapy
Number of subjects: 40
Study 25304729 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α therapy (3 MU 3 times weekly)
Number of subjects: 48
Study 25304729 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group
Number of subjects: 48
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Core module (baseline, six, and 12 months)
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Snapshot module (months three and nine)
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Core module
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities/Endophenotypes module
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Burden (Proband) module
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Burden (Partner) module
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Burden (Child) module
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Snapshot module (three months)
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Core module (six months)
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Snapshot module (nine months)
Number of subjects: 16789
Study 25304766 — intervention group
Group type: EXPERIMENTAL
Intervention: Core module (12 months)
Number of subjects: 16789
Study 25304853 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aspirin therapy
Number of subjects: 14041
Study 25305371 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral cane use
Number of subjects: 38
Study 25305371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral cane use
Number of subjects: 38
Study 25305371 — intervention group
Group type: COMPARATOR
Intervention: No cane
Number of subjects: 38
Study 25305371 — intervention group
Group type: COMPARATOR
Intervention: Contralateral cane use vs Ipsilateral cane use
Number of subjects: 38
Study 25305705 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (ALIS)
Number of subjects: 13433
Study 25305705 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor/angiotensin receptor blocker (ACEI/ARB)
Number of subjects: 13433
Study 25305705 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive agent not affecting the renin angiotensin system (non-RAS)
Number of subjects: 13433
Study 25305705 — intervention group
Group type: COMPARATOR
Intervention: All groups (ALIS, ACEI/ARB, non-RAS)
Number of subjects: 13433
Study 25306425 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 11
Study 25307045 — intervention group
Group type: EXPERIMENTAL
Intervention: SIAscopy
Number of subjects: 0
Study 25307417 — intervention group
Group type: EXPERIMENTAL
Intervention: School-wide positive behavioral interventions and supports (PBIS)
Number of subjects: 0